The Phase 1 trial of allopregnanolone for mild cognitive impairment (MCI) and early Alzheimer's disease (AD) aims to establish safety and tolerability, with a focus on determining the maximally tolerated dose. Given the increasing prevalence of Alzheimer's disease and the limited treatment options available, successful outcomes could position allopregnanolone as a novel therapeutic approach in a competitive market. The collaboration with the National Institute on Aging (NIA) enhances credibility and may facilitate future funding opportunities. The trial's completion in February 2018 indicates that further analysis and potential progression to later phases could attract interest from larger pharmaceutical companies looking to expand their neurology portfolios.